Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Celldex Couldn’t Sway FDA On Rintega

This article was originally published in The Pink Sheet Daily

Executive Summary

Although it yielded impressive survival data compared to standard of care, the Phase II ReACT study was not powered for efficacy, so FDA is requiring Phase III data as well despite the need in glioblastoma.


Related Content

Faster FDA Review A Possibility For Celldex’s Rintega After Phase II


Related Companies